5 Undervalued U.S. Stocks With Improving Fundamentals Despite Weak Share Performance

Reference date: 2026-08-25

Rank 1. CVS Health (CVS) Investment Score: 9.0/10 1) Last 3 months: Sentiment remained cautious despite improving fundamentals. 2) Latest revenue growth: $106.1B, up 7.3% YoY. 3) Operating margin trend: Operating income improved significantly to $4.7B. 4) Free cash flow trend: YTD operating cash flow reached $10.6B. 5) Debt and cash: Strong cash-generation profile; latest net cash figure not confirmed. 6) Guidance: Raised 2026 EPS and cash-flow guidance. 7) Valuation: Trading below historical valuation norms. 8) Key risk: Rising medical costs and insurance-margin pressure. Upside drivers: Healthcare-benefits recovery and stronger cash generation.

Rank 2. Pfizer (PFE) Investment Score: 8.7/10 1) Last 3 months: Stock pressured by growth concerns. 2) Latest revenue growth: $15.0B revenue, +1% operational growth; +5% excluding COVID products. 3) Operating margin trend: Ongoing productivity and cost-efficiency improvements. 4) Free cash flow trend: Improving, but latest quarterly figure could not be verified. 5) Debt and cash: Maintains large-cap pharmaceutical liquidity strength. 6) Guidance: Increased midpoint of annual revenue guidance by $500M. 7) Valuation: Below sector-average valuation metrics. 8) Key risk: Patent expirations and pipeline execution risk. Upside drivers: Growth in non-COVID portfolio and productivity initiatives.

Rank 3. PayPal (PYPL) Investment Score: 8.5/10 1) Last 3 months: Underperformed many growth peers. 2) Latest revenue growth: $8.7B, up 5% YoY. 3) Operating margin trend: Non-GAAP operating margin declined to 17.4%. 4) Free cash flow trend: Improved sharply to approximately $1.8B. 5) Debt and cash: $15.3B cash and investments versus $13.4B debt. 6) Guidance: Raised full-year EPS outlook. 7) Valuation: Trades below historical averages. 8) Key risk: Competitive pressure and fee compression. Upside drivers: Venmo growth, payment-volume expansion, and buybacks.

Rank 4. Target (TGT) Investment Score: 8.1/10 1) Last 3 months: Limited performance amid consumer-spending concerns. 2) Latest revenue growth: $26.5B, up 5.3% YoY. 3) Operating margin trend: Improved to roughly 9.6%. 4) Free cash flow trend: Positive improvement trend. 5) Debt and cash: Maintains investment-grade balance-sheet quality. 6) Guidance: Raised annual outlook. 7) Valuation: Below long-term historical averages. 8) Key risk: Consumer spending weakness and price competition. Upside drivers: Digital sales growth of 8.7% and higher traffic.

Rank 5. Nike (NKE) Investment Score: 7.8/10 1) Last 3 months: Long-term underperformance persisted. 2) Latest revenue growth: $11.7B, up 1% YoY. 3) Operating margin trend: Margin pressure remains. 4) Free cash flow trend: Remains positive. 5) Debt and cash: Approximately $8.6B cash versus about $11.1B debt. 6) Guidance: Near-term revenue pressure but restructuring continues. 7) Valuation: Significantly discounted versus historical premium levels. 8) Key risk: China demand weakness and margin pressure. Upside drivers: Running-category momentum and wholesale recovery.

Conclusion For a 6-18 month horizon, CVS Health and Pfizer offer the strongest combination of valuation support and improving fundamentals. PayPal remains a credible turnaround candidate, while Target and Nike provide valuation-driven opportunities with higher cyclical risk.

Facts and company guidance have been separated where possible, and unavailable figures were not estimated.